Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
DRRX

DRRX - Durect Corp Stock Price, Fair Value and News

$1.91 
Market Closed

Price Targets

DRRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DRRX Price Action

Last 7 days

-0.5%

Last 30 days

2.7%

Last 90 days

253.7%

Trailing 12 Months

17.9%

DRRX RSI Chart

DRRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DRRX Valuation

Market Cap

59.3M

Price/Earnings (Trailing)

-17.05

Price/Sales (Trailing)

29.36

Price/Free Cashflow

-4.27

DRRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

DRRX Fundamentals

DRRX Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

-30.8%

Rev. Growth (Qtr)

39.25%

DRRX Earnings

Earnings (TTM)

-3.5M

Earnings Growth (Yr)

38.78%

Earnings Growth (Qtr)

46.48%

DRRX Profitability

Return on Equity

-99.86%

Return on Assets

-27.86%

Free Cashflow Yield

-23.41%

DRRX Investor Care

Shares Dilution (1Y)

0.05%

Diluted EPS (TTM)

-0.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20242.5M2.3M2.2M2.0M
202315.9M9.3M5.9M2.6M
202213.7M13.5M23.3M19.3M
202130.7M8.5M8.9M14.0M
202026.3M27.6M28.9M30.1M
201919.2M19.8M21.5M25.1M
201848.1M47.2M34.5M18.6M
201715.0M16.1M33.1M49.2M
201618.0M16.7M15.7M14.0M
201517.9M17.7M18.2M19.1M
201417.5M18.1M19.4M19.4M
201316.0M15.2M14.3M15.3M
201266.1M63.0M58.7M53.1M
201132.5M33.0M33.0M33.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Durect Corp

DRRX
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
 CEO
 WEBSITEdurect.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES72

Durect Corp Frequently Asked Questions

DRRX is the stock ticker symbol of Durect Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Sep 11 2025, market cap of Durect Corp is 59.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check DRRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether DRRX is over valued or under valued. Whether Durect Corp is cheap or expensive depends on the assumptions which impact Durect Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DRRX.

As of Thu Sep 11 2025, DRRX's PE ratio (Price to Earnings) is -17.05 and Price to Sales (PS) ratio is 29.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DRRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Durect Corp has provided -0.216 (multiply by 100 for percentage) rate of return.